Clinical Data Appoints Carol Reed Chief Medical Officer and John Schultz Senior Vice President, Business Development.

NEWTON, Mass. -- Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

CLINICAL DATA APPOINTS CAROL REED CHIEF MEDICAL OFFICER AND JOHN SCHULTZ SENIOR VICE PRESIDENT, BUSINESS DEVELOPMENT

Seasoned Executives to Expand Senior Management Team

Clinical Data, Inc. (NASDAQ:CLDA) today announced the appointment of two new key members of the company's senior management team: Carol Reed, M.D., as Senior Vice President and Chief Medical Officer, and John A. Schultz, as Senior Vice President, Business Development.

Dr. Reed is joining Clinical Data following the completion of the company's previously announced merger with Genaissance Pharmaceuticals, Inc., where Dr. Reed served as that company's Vice President, Medical Affairs since 2003. In her new role with Clinical Data, Dr. Reed, 52, will be responsible for Clinical Data's drug-specific partnership collaborations and clinical programs. Dr. Reed joined Genaissance from Bayer Pharmaceuticals, Inc., where she was an Associate Medical Director in Pulmonary Medical Research. Previously, she was the Associate Director, Section of Pulmonary and Critical Care Medicine at the Hospital of St. Raphael and directed its Medical Intensive Care Unit. Dr. Reed received a M.S. in Molecular Biology from the University of Illinois and a M.D. from the Rush Medical College in Chicago.

In the newly created position of Senior Vice President, Business Development, Mr. Schultz will be responsible for developing and managing Clinical Data's business opportunities in the pharmacogenomics and biomarker diagnostics markets. Mr. Schultz, 43, most recently was Vice President, Business Development of Pathway Diagnostics Corporation, where he was responsible for the development of biomarker diagnostics business opportunities and out-licensing activities. Prior to Pathway Diagnostics, Mr. Schultz headed the Life Sciences Business Development activities at the Office of Intellectual Property Administration at UCLA, and prior to that position was Director of Business Development at Specialty Laboratories where he spearheaded their licensing activities. Mr. Schultz also has extensive experience in the clinical diagnostics market, including serving as General Manager for the ImmunoSystems' Division of BioChem Pharma (now Shire Pharmaceuticals), as well as positions at Sigma-Aldrich Corp., Isolab Inc. (now Perkin Elmer) and Mallinckrodt's Forma Scientific Division (now Thermo Electron).Mr. Schultz holds a Bachelor of Science degree from Washington State University and a Master of Business Administration Degree from The Garvin School of International Management.

Israel M. Stein, MD, President and CEO of Clinical Data commented. "We are delighted to add seasoned senior executives of Carol and John's caliber to the CLDA team, as we expand our diagnostic business into major new opportunities in the pharmacogenomics market."

About Clinical Data, Inc.

Clinical Data, Inc. is a worldwide leader in developing and commercializing pharmacogenomics and clinical diagnostics to improve patient care. The Company's genomic services are marketed to the pharmaceutical, biotech, diagnostic, academic and agricultural marketplaces. The Company is utilizing pharmacogenomics to develop molecular diagnostics and more efficacious therapeutics by finding genetic markers to guide drug development and utilization. Our diagnostics and instrumentation business has a market focus on the physician office, hospital and small to medium sized laboratory segments.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information that are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: those discussed and identified in public filings with the U.S. Securities and Exchange Commission made by CLDA; significant acquisitions or divestitures by major competitors; our ability to consummate our announced acquisition of Icoria, Inc.,and to achieve expected synergies and operating efficiencies in all of our acquisitions, and to successfully integrate our operations. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. CLDA does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in CLDA's various SEC reports, including but not limited to its Annual Report on Form 10-KSB for the fiscal year ended March 31, 2005, and 2004 and 2005 quarterly reports on Form 10-QSB and 10-Q.